Abstract
Cholinergic deficit is a cardinal feature of Alzheimers disease, and cholinesterase inhibitors represent one of the most prominent means of mitigating this dysfunction. Cholinesterase inhibitors provide mild symptomatic relief, although they lose their efficacy over time most likely because they are not disease-modifying agents. An alternative strategy for restoring cholinergic function and attenuating the cognitive decline involves acting on the receptors on which acetylcholine acts. Stimulation of muscarinic acetylcholine receptors and in particular the M1 subtype has been shown to have a beneficial effect in restoring cognition in patients with Alzheimers disease and in attenuating Aβ and tau pathology in different animal models. In this review, we discuss the role of M1 agonists as a potential disease – modifying therapy for Alzheimers disease.
Keywords: M1 Agonists, Alzheimer's disease, cholinesterase inhibitors, acetylcholine receptors, cholinergic neurons
Current Alzheimer Research
Title: M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease
Volume: 6 Issue: 2
Author(s): Antonella Caccamo, Abraham Fisher and Frank M. LaFerla
Affiliation:
Keywords: M1 Agonists, Alzheimer's disease, cholinesterase inhibitors, acetylcholine receptors, cholinergic neurons
Abstract: Cholinergic deficit is a cardinal feature of Alzheimers disease, and cholinesterase inhibitors represent one of the most prominent means of mitigating this dysfunction. Cholinesterase inhibitors provide mild symptomatic relief, although they lose their efficacy over time most likely because they are not disease-modifying agents. An alternative strategy for restoring cholinergic function and attenuating the cognitive decline involves acting on the receptors on which acetylcholine acts. Stimulation of muscarinic acetylcholine receptors and in particular the M1 subtype has been shown to have a beneficial effect in restoring cognition in patients with Alzheimers disease and in attenuating Aβ and tau pathology in different animal models. In this review, we discuss the role of M1 agonists as a potential disease – modifying therapy for Alzheimers disease.
Export Options
About this article
Cite this article as:
Caccamo Antonella, Fisher Abraham and LaFerla M. Frank, M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease, Current Alzheimer Research 2009; 6(2) . https://dx.doi.org/10.2174/156720509787602915
DOI https://dx.doi.org/10.2174/156720509787602915 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents Role of Artificial Intelligence Techniques (Automatic Classifiers) in Molecular Imaging Modalities in Neurodegenerative Diseases
Current Alzheimer Research Hypothermia and Alzheimer's Disease Neuropathogenic Pathways
Current Alzheimer Research Mitochondrial Deficits Accompany Cognitive Decline Following Single Bilateral Intracerebroventricular Streptozotocin
Current Alzheimer Research Alcohol Consumption, Dementia and Cognitive Decline: An Overview of Systematic Reviews
Current Clinical Pharmacology Cross-Cultural Comparison of Mild Cognitive Impairment between China and USA
Current Alzheimer Research Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Molecular Linkages Between Diabetes and Alzheimer's Disease: Current Scenario and Future Prospects
CNS & Neurological Disorders - Drug Targets Different Effect of Vitamin D<sub>2</sub> and Vitamin D<sub>3</sub> on Amyloid-β40 Aggregation In Vitro
Current Alzheimer Research n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Complex Polyamines: Unique Prion Disaggregating Compounds
CNS & Neurological Disorders - Drug Targets Modulation of Monoaminergic Transporters by Choline-Containing Phospholipids in Rat Brain
CNS & Neurological Disorders - Drug Targets Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research The Effects of Cognitive Speed of Processing Training Among Older Adults with Psychometrically- Defined Mild Cognitive Impairment
Current Alzheimer Research Salidroside - Can it be a Multifunctional Drug?
Current Drug Metabolism Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Assessment of the Autonomic Response in Alzheimer's Patients During the Execution of Memory Tasks: A Functional Thermal Imaging Study
Current Alzheimer Research Editorial (Thematic Issue: Mitochondria and Subcellular Organelles as Treatment Targets Against Pathological Conditions)
Current Pharmaceutical Design Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets